For multiple myeloma. Sold as Aphexda. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Motixafortide Acetate (sold as Aphexda), first approved Sep 8, 2023, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Aphexda | Part B | $1.3M | +44% | 101 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialMultiple Myeloma · Emory University | Phase 4 | Recruiting | Aug 3, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 8, 2023 | AphexdaNDA 217159 · New molecular entity | Ayrmid Pharma | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA